Elutia Secures Up To $26M Of Additional Capital To Support NXT-41x Clearance And Its First Full Year Of Commercial Launch In 2028
Funded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand is strong: 96% of
Elutia got $26 million in money to help launch a new surgical product next year. This shows the company has support to grow, and many surgeons say they need a better product like this one.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.